Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Apellis Pharmaceuticals, Inc. to Biogen Inc. to assess the adequacy of the price and process involved in the transaction [1]. Summary by Relevant Sections - **Proposed Transaction Details** - Apellis shareholders are set to receive $41.00 per share in cash along with a nontransferable contingent value right for two additional payments of $2.00 per share, contingent on meeting specific annual global net sales thresholds for SYFOVRE [1]. - **Investigation Purpose** - The investigation aims to determine whether the proposed consideration undervalues Apellis Pharmaceuticals and whether the process leading to this valuation was adequate [1]. - **Contact Information for Investors** - Investors who believe the transaction undervalues the company can contact Kahn Swick & Foti, LLC for further discussion regarding their legal rights [2].

Core Viewpoint - Laird Superfood anticipates significant distribution gains from its recent acquisition of Navitas, a California-based organic food and drinks business, which was completed for $38.5 million [1][4]. Group 1: Acquisition Details - The acquisition of Navitas includes a diverse range of organic products such as acai powder, hemp seeds, and powdered lattes [1]. - CEO Jason Vieth highlighted that the deal will enhance sales and allow for a more impactful market presence with two strong brands [3]. Group 2: Market Position and Strategy - There is considerable overlap in the retail channels of Laird Superfood and Navitas, particularly with major retailers like Whole Foods and Sprouts, which aligns with Laird's existing portfolio [2]. - The integration of both brands is expected to create assortment opportunities, leveraging one brand to enhance the other [4]. Group 3: Financial Backing - Laird Superfood secured investment from Nexus Capital Management to fund the acquisition, with Nexus purchasing an initial tranche of 50,000 shares at $1,000 per share [5]. - Nexus now holds over half of Laird Superfood's publicly-listed shares, and additional proceeds from Nexus are intended for future acquisitions or growth initiatives [6].

Core Viewpoint - The joint press release announces that Kodiak BidCo B.V. has successfully completed a public cash offer for JDE Peet's N.V., with 96.22% of shares tendered, leading to the offer being declared unconditional [2][8]. Offer Details - The Offer Period ended on 27 March 2026, with 466,712,270 shares tendered, valued at approximately EUR 14.86 billion [2][8]. - Settlement of the Offer is scheduled for 1 April 2026, with payment for tendered shares to be made on that date [4][8]. Post-Closing Acceptance Period - A post-closing acceptance period will commence on 30 March 2026 and end on 13 April 2026, allowing shareholders who did not tender their shares to do so under the same terms [6][8]. - The Offeror will announce the results of this period by the third business day following its conclusion [7]. Board Composition Changes - Changes to the Board composition, approved by the Extraordinary General Meeting on 2 March 2026, will take effect upon settlement [5]. Delisting and Buy-Out Proceedings - Following the unconditional declaration of the Offer, the delisting of JDE Peet's shares from Euronext Amsterdam will be pursued [11]. - The Offeror plans to initiate statutory Buy-Out Proceedings after the post-closing acceptance period [12]. Company Profiles - Keurig Dr Pepper Inc. (KDP) is a leading beverage company in North America with over 125 brands and annual revenue exceeding $16 billion [16]. - JDE Peet's is the world's leading pure-play coffee company, generating EUR 9.9 billion in sales in 2025 and operating in over 100 markets [18].

Core Viewpoint - Keurig Dr Pepper Inc. has successfully declared its public cash offer for JDE Peet's unconditional, with 96.22% of shares tendered during the offer period, amounting to approximately EUR 14.86 billion [2][6]. Offer Details - The offer period expired on March 27, 2026, at 17:40 CET, with a total of 466,712,270 shares tendered, representing 96.22% of all shares [2][6]. - The settlement date for the offer is set for April 1, 2026, where payment for each tendered share will be made [3][6]. - Shareholders who did not tender their shares during the offer period will have a post-closing acceptance period from March 30, 2026, to April 13, 2026, to tender their shares under the same terms [5][6]. Post-Closing Measures - Following the post-closing acceptance period, the offeror will initiate statutory buy-out proceedings and may implement a post-closing demerger [11]. - The offeror will announce the results of the post-closing acceptance period and the total number of shares held by it within three business days after the period ends [7]. Delisting and Board Changes - The shares of JDE Peet's will be delisted from Euronext Amsterdam as soon as possible following the declaration of the offer as unconditional [10]. - Changes to the composition of the board, approved by the extraordinary general meeting on March 2, 2026, will take effect upon settlement [4]. Company Background - Keurig Dr Pepper is a leading beverage company in North America with over 125 brands and annual revenue exceeding $16 billion [14]. - JDE Peet's is recognized as the world's leading pure-play coffee company, generating total sales of EUR 9.9 billion in 2025 [15].

Core Viewpoint - Eldorado Gold Corporation has received a recommendation from Institutional Shareholder Services (ISS) to approve the issuance of shares in connection with the proposed acquisition of Foran Mining Corporation, which is expected to enhance Eldorado's long-term growth profile [1][4]. Group 1: Transaction Details - The special meeting for Eldorado shareholders to vote on the Eldorado Share Issuance Resolution is scheduled for April 7, 2026 [2]. - Under the proposed arrangement, Eldorado will acquire all issued and outstanding Foran common shares, with each Foran shareholder receiving 0.1128 of an Eldorado share and CAD$0.01 in cash for each Foran share held [3]. - Upon completion of the arrangement, Foran will become a wholly-owned subsidiary of Eldorado [3][7]. Group 2: Recommendations - ISS has recommended that shareholders vote in favor of the Eldorado Share Issuance Resolution, highlighting the merits of the transaction [4]. - Eldorado's Board of Directors unanimously supports the resolution and encourages shareholders to vote early [5][7]. Group 3: Strategic Rationale - The transaction aligns with Eldorado's strategic goals and is expected to strengthen its growth profile through a disciplined and value-focused combination with Foran [7]. - Independent fairness opinions were obtained to support the transaction [7]. Group 4: Shareholder Engagement - Shareholders are encouraged to vote as early as possible, with a proxy voting deadline set for April 2, 2026 [6]. - Assistance for voting and questions can be directed to Laurel Hill Advisory Group [6][8]. Group 5: Company Overview - Eldorado Gold is a producer of gold and base metals with operations in Canada, Greece, and Türkiye, known for its skilled workforce and high-quality asset portfolio [9].

Core Viewpoint - Merck is acquiring Terns Pharmaceuticals for $6.7 billion, marking its third multibillion-dollar acquisition in the past year as it prepares for the patent expiration of its leading cancer drug Keytruda in 2028 [1] Group 1: Acquisition Details - The acquisition price for Terns Pharmaceuticals is $6.7 billion [1] - This acquisition is part of Merck's strategy to strengthen its portfolio ahead of Keytruda's patent loss [1] Group 2: Market Reaction - Following the announcement, Terns shares increased by 5.3% [1] - Merck's stock remained largely unchanged in premarket trading [1]

Core Viewpoint - Canadian Uranium has signed an agreement to acquire all issued and outstanding common shares of Rook 2 Uranium through a three-cornered amalgamation, which will enhance its asset portfolio in the uranium sector [1][5]. Group 1: Transaction Details - The agreement involves Rook 2 merging with a newly formed subsidiary of Canadian Uranium, with Rook 2 shareholders receiving one share of Canadian Uranium for each share they hold in Rook 2 [2]. - A total of approximately 9,663,156 shares of Canadian Uranium will be issued to Rook 2 shareholders as consideration for the outstanding shares [2]. - The completion of the transaction is subject to customary conditions, including regulatory approvals and consent from Rook 2 shareholders [3]. Group 2: Asset and Strategic Importance - Rook 2 holds an exclusive option to secure full ownership of 21 mineral claims covering approximately 18,941 hectares in Saskatchewan, which is a significant asset in the uranium industry [1]. - The Rook 2 asset is considered particularly valuable due to its location in the prolific Athabasca Basin, which is known for its historic resources [5]. - Canadian Uranium aims to build a strong team and company based on the foundation laid over the past three years, indicating a strategic focus on growth and development in the uranium sector [4][5].

Group 1: Acquisition Consideration - US-based packaging company Silgan Holdings is considering a possible acquisition of German medical packaging manufacturer Gerresheimer, with a potential valuation of €41 ($47.22) per share [1] - Silgan is currently working with advisers on the proposal, but it remains uncertain whether a formal bid will be made or if any deal will be finalized [1] Group 2: Gerresheimer's Financial Challenges - Gerresheimer's market capitalization is currently €600 million ($694 million), with its share price having dropped more than 80% from its highs in 2023 and falling by 37% since the beginning of this year [2] - The company is facing significant challenges, including an expanded examination of its financial statements by Germany's financial regulator BaFin [2][3] Group 3: Silgan's Financial Performance - For the fourth quarter of 2025, Silgan reported net income of $18.2 million, down from $45.1 million in the same period of 2024 [3] - Silgan's full-year net income for 2025 rose to $288.4 million from $276.4 million in 2024 [3] - The company has projected adjusted net income per diluted share to range from $3.7 to $3.9 for 2026, a modest rise from its midpoint adjusted figure of $3.72 for 2025 [4] Group 4: Previous Acquisitions - In the previous year, Silgan completed its acquisition of Weener Plastics, a Dutch dispensing solutions provider, in a transaction valued at €838 million ($908 million) [4]

Group 1 - The transaction aims to create a single group that integrates two of Italy's largest industrial companies [1]

Core Viewpoint - Diana Shipping Inc. urges Genco Shipping & Trading Limited's Board to engage in good faith negotiations regarding Diana's fully financed cash offer of $23.50 per share for Genco's outstanding shares not already owned by Diana, emphasizing that the proposal presents a premium valuation opportunity for Genco shareholders [1][2][15]. Financing and Proposal Details - Diana's offer is fully financed with a total commitment of $1.433 billion, which includes $1.102 billion for acquisition debt financing and an additional $331 million for voluntary refinancing of Diana's existing debt [3][4]. - The financing is not contingent on the sale of vessels to Star Bulk, and Genco is aware of the financing structure, which supports the completion of the proposed transaction [3][4]. Genco Board's Response - The Genco Board has rejected Diana's proposal without seeking clarification, raising unfounded questions about the financing, which Diana claims are disproven by public disclosures [2][3]. - Diana asserts that Genco's actions indicate a focus on entrenchment rather than maximizing shareholder value, prompting Diana to pursue the election of independent directors to the Genco Board [4]. Shareholder Engagement - Diana calls on Genco shareholders to encourage the Board to consider the premium offer and explore all meaningful opportunities for value creation [4].